Scleroderma Drug Developer iBio Announces U.S. Patent for iBioModulatorâ„¢ Thermostable Immunomodulator Protein Portfolio
iBio, Inc. recently announced the release of a U.S. patent for a new thermostable immunomodulator protein portfolio called iBioModulatorâ„¢. The company’s iBioModulatorâ„¢ thermostable immunomodulator protein patents, entitled “Yersinia pests Antigens, Vaccine Compositions and Related Methods,” (Serial No. 8,945,580), includes statements about plague antigens, vaccine compositions, and a technique that produces…